Segment Information (Tables)

3 Months Ended

Mar. 31, 2014



	Three Months Ended
	March 31,
	2014			2013
Segment revenue—to unaffiliated customers:
Human pharmaceutical products:
Endocrinology	$	1,639.2		$	1,724.9
Neuroscience	964.4			1,848.8
Oncology	764.3			764.2
Cardiovascular	712.8			693.9
Other pharmaceuticals	75.0			71.1
Total human pharmaceutical products	4,155.7			5,102.9
Animal health	527.4			499.1
Total segment revenue	$	4,683.1		$	5,602.0
Segment profits⁽¹⁾:
Human pharmaceutical products	$	787.8		$	1,348.2
Animal health	134.4			129.2
Total segment profits	$	922.2		$	1,477.4
Reconciliation of total segment profits to consolidated income before taxes:
Segment profits	$	922.2		$	1,477.4
Other profits (losses):
Income related to termination of the exenatide collaboration with Amylin (Note 4)	—			495.4
Asset impairment, restructuring, and other special charges (Note 5)	(31.4		)	(21.7		)
Total consolidated income before taxes	$	890.8		$	1,951.1

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details